TY - JOUR
T1 - Making sense of current and emerging therapies in pancreatic cancer
T2 - balancing benefit and value
AU - Ahn, Daniel H.
AU - Ko, Andrew H.
AU - Meropol, Neal J.
AU - Bekaii-Saab, Tanios S.
PY - 2015
Y1 - 2015
N2 - Pancreatic cancer remains the fourth leading cause of cancer deaths in the United States with a dismal prognosis and a 5-year survival of less than 5% across all stages.(1) In 2014, there were approximately 46,420 new cases of pancreatic cancer with only 9% of patients having localized disease.(2) Given that the vast majority of patients present with advanced disease, much of the focus for drug development has been in the metastatic setting, which is evident with the advent of two combination chemotherapy regimens for this indication. Although conventional cytotoxic chemotherapy remains the standard of care, an ongoing search for novel therapeutic approaches continues. We will highlight several new approaches here, with a particular emphasis on immunotherapeutic strategies. We will also introduce concepts regarding the potential economic effects associated with the development and implementation of new treatments in pancreatic cancer.
AB - Pancreatic cancer remains the fourth leading cause of cancer deaths in the United States with a dismal prognosis and a 5-year survival of less than 5% across all stages.(1) In 2014, there were approximately 46,420 new cases of pancreatic cancer with only 9% of patients having localized disease.(2) Given that the vast majority of patients present with advanced disease, much of the focus for drug development has been in the metastatic setting, which is evident with the advent of two combination chemotherapy regimens for this indication. Although conventional cytotoxic chemotherapy remains the standard of care, an ongoing search for novel therapeutic approaches continues. We will highlight several new approaches here, with a particular emphasis on immunotherapeutic strategies. We will also introduce concepts regarding the potential economic effects associated with the development and implementation of new treatments in pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=84965185427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84965185427&partnerID=8YFLogxK
U2 - 10.14694/EdBook_AM.2015.35.e222
DO - 10.14694/EdBook_AM.2015.35.e222
M3 - Review article
C2 - 25993177
AN - SCOPUS:84965185427
SN - 1548-8756
SP - e222-e227
JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
ER -